In July, the U.S. Food & Drug Administration (FDA) made two announcements regarding IBD treatments: New HUMIRA® biosimilar approved for ulcerative colitis and adult Crohn’s disease patients The FDA announced the approval of HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMI...